Cargando…

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

PURPOSE: Human papillomavirus (HPV) DNA offers a convenient circulating tumor DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital PCR (dPCR), provide insufficient accuracy for clinical applications in patients with low disease burden. We asked whether a next-gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Eric, Han, Kathy, Zou, Jinfeng, Zhao, Zhen, Zheng, Yangqiao, Wang, Ting Ting, Rostami, Ariana, Siu, Lillian L., Pugh, Trevor J., Bratman, Scott V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401563/
https://www.ncbi.nlm.nih.gov/pubmed/34580115
http://dx.doi.org/10.1158/1078-0432.CCR-19-2384
_version_ 1784772990624333824
author Leung, Eric
Han, Kathy
Zou, Jinfeng
Zhao, Zhen
Zheng, Yangqiao
Wang, Ting Ting
Rostami, Ariana
Siu, Lillian L.
Pugh, Trevor J.
Bratman, Scott V.
author_facet Leung, Eric
Han, Kathy
Zou, Jinfeng
Zhao, Zhen
Zheng, Yangqiao
Wang, Ting Ting
Rostami, Ariana
Siu, Lillian L.
Pugh, Trevor J.
Bratman, Scott V.
author_sort Leung, Eric
collection PubMed
description PURPOSE: Human papillomavirus (HPV) DNA offers a convenient circulating tumor DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital PCR (dPCR), provide insufficient accuracy for clinical applications in patients with low disease burden. We asked whether a next-generation sequencing approach, HPV sequencing (HPV-seq), could provide quantitative and qualitative assessment of HPV ctDNA in low disease burden settings. EXPERIMENTAL DESIGN: We conducted preclinical technical validation studies on HPV-seq and applied it retrospectively to a prospective multicenter cohort of patients with locally advanced cervix cancer (NCT02388698) and a cohort of patients with oropharynx cancer. HPV-seq results were compared with dPCR. The primary outcome was progression-free survival (PFS) according to end-of-treatment HPV ctDNA detectability. RESULTS: HPV-seq achieved reproducible detection of HPV DNA at levels less than 0.6 copies in cell line data. HPV-seq and dPCR results for patients were highly correlated (R(2) = 0.95, P = 1.9 × 10(–29)) with HPV-seq detecting ctDNA at levels down to 0.03 copies/mL plasma in dPCR-negative posttreatment samples. Detectable HPV ctDNA at end-of-treatment was associated with inferior PFS with 100% sensitivity and 67% specificity for recurrence. Accurate HPV genotyping was successful from 100% of pretreatment samples. HPV ctDNA fragment sizes were consistently shorter than non–cancer-derived cell-free DNA (cfDNA) fragments, and stereotyped cfDNA fragmentomic patterns were observed across HPV genomes. CONCLUSIONS: HPV-seq is a quantitative method for ctDNA detection that outperforms dPCR and reveals qualitative information about ctDNA. Our findings in this proof-of-principle study could have implications for treatment monitoring of disease burden in HPV-related cancers. Future prospective studies are needed to confirm that patients with undetectable HPV ctDNA following chemoradiotherapy have exceptionally high cure rates.
format Online
Article
Text
id pubmed-9401563
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-94015632023-01-05 HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA Leung, Eric Han, Kathy Zou, Jinfeng Zhao, Zhen Zheng, Yangqiao Wang, Ting Ting Rostami, Ariana Siu, Lillian L. Pugh, Trevor J. Bratman, Scott V. Clin Cancer Res Precision Medicine and Imaging PURPOSE: Human papillomavirus (HPV) DNA offers a convenient circulating tumor DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital PCR (dPCR), provide insufficient accuracy for clinical applications in patients with low disease burden. We asked whether a next-generation sequencing approach, HPV sequencing (HPV-seq), could provide quantitative and qualitative assessment of HPV ctDNA in low disease burden settings. EXPERIMENTAL DESIGN: We conducted preclinical technical validation studies on HPV-seq and applied it retrospectively to a prospective multicenter cohort of patients with locally advanced cervix cancer (NCT02388698) and a cohort of patients with oropharynx cancer. HPV-seq results were compared with dPCR. The primary outcome was progression-free survival (PFS) according to end-of-treatment HPV ctDNA detectability. RESULTS: HPV-seq achieved reproducible detection of HPV DNA at levels less than 0.6 copies in cell line data. HPV-seq and dPCR results for patients were highly correlated (R(2) = 0.95, P = 1.9 × 10(–29)) with HPV-seq detecting ctDNA at levels down to 0.03 copies/mL plasma in dPCR-negative posttreatment samples. Detectable HPV ctDNA at end-of-treatment was associated with inferior PFS with 100% sensitivity and 67% specificity for recurrence. Accurate HPV genotyping was successful from 100% of pretreatment samples. HPV ctDNA fragment sizes were consistently shorter than non–cancer-derived cell-free DNA (cfDNA) fragments, and stereotyped cfDNA fragmentomic patterns were observed across HPV genomes. CONCLUSIONS: HPV-seq is a quantitative method for ctDNA detection that outperforms dPCR and reveals qualitative information about ctDNA. Our findings in this proof-of-principle study could have implications for treatment monitoring of disease burden in HPV-related cancers. Future prospective studies are needed to confirm that patients with undetectable HPV ctDNA following chemoradiotherapy have exceptionally high cure rates. American Association for Cancer Research 2021-11-01 2021-09-27 /pmc/articles/PMC9401563/ /pubmed/34580115 http://dx.doi.org/10.1158/1078-0432.CCR-19-2384 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Precision Medicine and Imaging
Leung, Eric
Han, Kathy
Zou, Jinfeng
Zhao, Zhen
Zheng, Yangqiao
Wang, Ting Ting
Rostami, Ariana
Siu, Lillian L.
Pugh, Trevor J.
Bratman, Scott V.
HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title_full HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title_fullStr HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title_full_unstemmed HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title_short HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
title_sort hpv sequencing facilitates ultrasensitive detection of hpv circulating tumor dna
topic Precision Medicine and Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401563/
https://www.ncbi.nlm.nih.gov/pubmed/34580115
http://dx.doi.org/10.1158/1078-0432.CCR-19-2384
work_keys_str_mv AT leungeric hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT hankathy hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT zoujinfeng hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT zhaozhen hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT zhengyangqiao hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT wangtingting hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT rostamiariana hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT siulillianl hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT pughtrevorj hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna
AT bratmanscottv hpvsequencingfacilitatesultrasensitivedetectionofhpvcirculatingtumordna